Bas van de Kar
Impact in
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research
- Pathology and Forensic Medicine top 10%
- Lymphoma Diagnosis and Treatment
Papers in
- Genetics 4
- Chronic Lymphocytic Leukemia Research 4
-
- Cancer Mechanisms and Therapy 1
- Co-authors
- Allard Kaptein (8 shared papers)Tjeerd A. Barf (8 shared papers)Edwin de Zwart (5 shared papers)Dennis Demont (5 shared papers)Raquel Izumi (1 shared paper)Bart van Lith (2 shared papers)Roger G. Ulrich (1 shared paper)Diana Mittag (2 shared papers)
- Journals
- Bioorganic & Medicinal Chemistry Letters (5 papers)Organic & Biomolecular Chemistry (1 paper)Journal of Pharmacology and Experimental Therapeutics (1 paper)Clinical Lymphoma Myeloma & Leukemia (1 paper)
- Partner nations
- NetherlandsSwitzerland
In The Last Decade
Bas van de Kar
8 papers receiving 397 citations
Peers
Comparison fields: 5 of 42
- Genetics 257
- Pathology and Forensic Medicine 164
- Hematology 87
- Organic Chemistry 91
- Immunology 59
Countries citing papers authored by Bas van de Kar
This map shows the geographic impact of Bas van de Kar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bas van de Kar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bas van de Kar more than expected).
Fields of papers citing papers by Bas van de Kar
This network shows the impact of papers produced by Bas van de Kar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bas van de Kar. The network helps show where Bas van de Kar may publish in the future.
Co-authors
The 25 scholars most cited alongside Bas van de Kar, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 327 | |
| 2 | 2015 | 25 | |
| 3 | 2011 | 20 | |
| 4 | 2011 | 18 | |
| 5 | 2011 | 13 | |
| 6 | 2020 | 7 | |
| 7 | 2021 | 3 | |
| 8 | 2019 | 1 |
About Bas van de Kar
Bas van de Kar is a scholar working on Genetics, Pathology and Forensic Medicine, Molecular Biology, Organic Chemistry and Hematology, having authored 8 papers that have together received 414 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (4 papers), Melanoma and MAPK Pathways (3 papers), Enzyme function and inhibition (2 papers), Synthesis and biological activity (2 papers), Cancer Mechanisms and Therapy (1 paper), Glycosylation and Glycoproteins Research (1 paper), Chronic Myeloid Leukemia Treatments (1 paper) and Quinazolinone synthesis and applications (1 paper). The work is most often cited by research in Genetics (257 citations), Pathology and Forensic Medicine (164 citations), Hematology (87 citations), Organic Chemistry (91 citations) and Immunology (59 citations). Bas van de Kar has collaborated with scholars based in Netherlands and Switzerland. Frequent co-authors include Allard Kaptein, Tjeerd A. Barf, Edwin de Zwart, Dennis Demont, Raquel Izumi, Bart van Lith, Roger G. Ulrich, Diana Mittag, Todd M. Covey and Fanny Krantz. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Organic & Biomolecular Chemistry, Journal of Pharmacology and Experimental Therapeutics and Clinical Lymphoma Myeloma & Leukemia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.